Episodes of GLI LIVE each Wednesday at noon ET to discuss the innovators changing the game for liver cancer care and prevention.Several patient highlights to elevate the stories of liver cancer survivors.The second annual Leadership in Liver Health Luncheon, during which GLI will honor trailblazers in health.Weekly Health Equity Roundtable conversations with leaders to discuss the unique challenges of liver cancer to LatinX, Black, Asian American, and LGBTQ+ people.There is something to look forward to all month! ![]() As GLI connects research, clinical, patient, and policy leaders, we will bring the daunting, nuanced challenges of this disease to the most brilliant minds in the field.” “We feel privileged at GLI to join with leaders across expertises and geographies to dive into candid conversation and to strengthen relationships. That is why it is so essential that we join as a global community to stop upstream risk factors, improve access to care, and create new methods for treatment,” shared Sarah Manes, Director of Liver Cancers Programs at GLI. “Liver cancer is a grim disease, and it poses a formidable challenge to the world. Similar inequity is evident across many demographic categories. In the U.S., for example, Asian American men are 70% more likely than non-Hispanic white men to develop liver cancer. This fact makes it more troubling that vulnerable populations, especially indigineous and ethnic minority communities around the world, bear a greater burden of liver cancers than majority populations. Tragically, around 70% of these cases of liver cancer could have been prevented by eliminating many modifiable risk factors. In South Korea, which has the best outcomes, just under 33% of people survive this long in the U.S., for instance, only 20% do. Five years after being diagnosed, less than a third of people are still alive. Throughout the month, GLI will use media, social media, educational expert panels, and other events to bring patients, survivors, caregivers, advocates, clinical experts, industry, and policymakers together around this critical issue.Ī liver cancer diagnosis provides a bleak outlook for over 900,000 people around the world each year. 01, 2022 (GLOBE NEWSWIRE) - Global Liver Institute (GLI) today launches its 5th annual #OctoberIs4Liver education and awareness campaign, which calls attention to liver cancer – the third deadliest cancer in the world. Gopalakrishnan, Director, CMFRI.Washington, D.C., Oct. The technology will be out-licensed soon to those in the pharmaceutical industry for commercial production of the nutraceutical.įor the past few years, the CMFRI has intensively focused on research on seaweed mainly for developing natural products beneficial to improving human health, said Dr. “It has proved that long-term oral administration of this product will not lead to general organ or systemic toxicity,” Dr. The nutraceutical does not have any side effects as established by detailed preclinical trials. This helps improve liver health, reduce the disposition of fatty substances, and maintain other liver/lipid parameters within the clinically acceptable limits,” he added. ![]() “Pre-clinical trials showed that LivCure extract proved to have the potential to inhibit different enzymes and various target receptors associated with dyslipidemia and pathophysiology leading to NAFLD. He said bioactive pharmacophore leads from seaweeds were used to develop the nutraceutical product. Kajal Chakraborty, Principal Scientist at the Marine Biotechnology, Fish Nutrition and Health Division of the CMFRI, led the research works to develop the product. This is the ninth such product from marine organisms developed by the CMFRI which had previously brought out nutraceuticals to combat a series of lifestyle diseases, such as Type-2 diabetes, arthritis, cholesterol, hypertension, hypothyroidism, and osteoporosis, and to improve immunity. Out of these nutraceuticals, eight products are from seaweed and one from green mussel, the release said.ĭr. Named Cadalmin TM LivCure extract, the product is a blend of 100% natural bioactive ingredients extracted from seaweed with an eco-friendly green technology to improve liver health, according to a press release from the CMFRI. Continuing its research on developing natural remedies from marine organisms against lifestyle diseases, the Central Marine Fisheries Research Institute (CMFRI) on Tuesday claimed it had developed a nutraceutical product from select seaweeds to treat non-alcoholic fatty liver disease (NAFLD).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |